Cellectar Biosciences Says Its Cash Balance Of $25.9M As Of June 30, 2024, When Combined With The $19.4M Raised In July, Is Adequate To Fund Its Basic Budgeted Operations Into The Second Quarter Of 2025
Portfolio Pulse from Benzinga Newsdesk
Cellectar Biosciences announced that its cash balance of $25.9M as of June 30, 2024, combined with $19.4M raised in July, is sufficient to fund its basic budgeted operations into the second quarter of 2025.
August 13, 2024 | 10:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellectar Biosciences has a cash balance of $25.9M as of June 30, 2024, and raised an additional $19.4M in July, ensuring funding for operations into Q2 2025.
The announcement of sufficient funding into Q2 2025 is a positive indicator for Cellectar Biosciences' financial stability, likely boosting investor confidence and supporting short-term stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100